Influence of age, frailty and liver function on the pharmacokinetics of brofaromine
Autor: | Bergmann W, L. Fuchs, P. R. Bieck, Zeeh J, K. H. Antonin, Degel F, Dieter Platt |
---|---|
Rok vydání: | 1996 |
Předmět: |
Adult
Male Aging medicine.medical_specialty Chromatography Gas Monoamine Oxidase Inhibitors Frail Elderly health care facilities manpower and services Administration Oral Pharmacology chemistry.chemical_compound Liver Function Tests Piperidines Pharmacokinetics Cytochrome P-450 CYP1A2 Caffeine Internal medicine Brofaromine medicine Humans Sorbitol Pharmacology (medical) Aged Aged 80 and over Geriatrics Cross-Over Studies biology medicine.diagnostic_test business.industry CYP1A2 General Medicine Crossover study Endocrinology chemistry biology.protein Regression Analysis Female Liver function Monoamine oxidase A business Liver function tests Half-Life |
Zdroj: | European Journal of Clinical Pharmacology. 49:387-391 |
ISSN: | 1432-1041 0031-6970 |
DOI: | 10.1007/bf00203783 |
Popis: | The pharmacokinetics of brofaromine, a selective inhibitor of monoamine oxidase A, was evaluated in 12 frail elderly patients (66-92 y) and 12 healthy volunteers (20-35 y).Quantitative liver function tests were performed to show whether brofaromine elimination in the elderly could be predicted from noninvasive assessment of CYP1A2 activity (caffeine clearance) or liver plasma flow (sorbitol clearance).In the elderly the AUC of brofaromine was significantly increased (e.g. for the 75 mg dose 43.2 vs 19.9 mumol*h.l-1, clearance was reduced (5.0 vs. 11.8 l.h-1), the volume of distribution was smaller (130 vs. 230 l), and the half-life was slightly increased (19.0 vs. 14.2 h). No significant correlation was observed between hepatic plasma flow and brofaromine clearance (r = 0.41, P = 0.05), whereas CYP1A2 activity and brofaromine clearance were tightly correlated (r = 0.94, P0.0001).Caffeine clearance, a simple, noninvasive test of CYP1A2 activity, is predictive of brofaromine clearance. |
Databáze: | OpenAIRE |
Externí odkaz: |